Pan-Neurofascin Nodo-Paranodopathy Presenting as Fulminant Guillain-Barre Syndrome
Neurol 105:e213848, Cabral,A.,et al, 2025
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Immunologic Aspects of Neurological & Neuromuscular Diseases
JAMA 258:2970-2973, Zweiman,B.&Arnason,B.G.W., 1987
Gold Encephalopathy
JNNP 40:1021, McAuley,D.L.F.,et al, 1977
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Spectrum of Paraneoplastic Disease Associated With Lymphoma
Neurol 76:705-710, Briani,C.,et al, 2011
Guillain-Barre Syndrome
BMJ 337:227-231, Winer,J.B., 2008
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
A 56-Year-Old Woman with New-Onset Hoarsement and Dysphagia
Neurol 104:e213363, McAree,M. & Frontera, J.A., 2025
An 8-Year-Old with Acute Onset Ataxia
Neurol 99:305-310, McLaren, J.R.,et al, 2022
Guillain-Barre Syndrome Associated with JEV Infection
NEJM 383:1188-1190, Wang, G.,et al, 2020
GQ1b-Seronegative Miller Fisher Syndrome Associated with Pembrolizumab
J Neuro-Ophthal 39:394-396, Green, K.E.,et al, 2019
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Acute Onset of Diplopia in Pregnancy
Neurol 91:e180-e184, Munro, Z. & Fernandez, D., 2018
Mycoplasma Pneumoniae Triggering the Guillain-Barre Syndrome
Ann Neurol 80:566-580, Meyer Sauteur, P.M.,et al, 2016
Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Paraparetic Guillain-Barre Syndrome
Neurol 82:1984-1989, Van Den Berg, B.,et al, 2014
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Campylobacter Gene Polymorphism as a Determinant of Clinical Features of Guillain-Barr Syndrome
Neurol 65:1376-1381,1350, Koga,M.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Guillain-Barre Syndrome Seen in Users of Isotretinoin
BMJ 328:1537, Pritchard,J.,et al, 2004
Practice Parameter:Immunotherapy for Guillain-Barre Syndrome, Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 61:736-740, Hughes,R.A.C.,et al, 2003
Guillain-Barre Syndrome Following Acute Falciparum Malaria
Neurol 59:1281-1283, Sakrab,T.O.,et al, 2002
Outcome in Severe Pediatric Guillain-Barre Syndrome after Immunotherapy or Supportive Care
Neurol 52:1494-1497, Graf,W.D.,et al, 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Prognostic Factors of Guillain-Barre Syndrome After Intravenous Immunoglobulin or Plasma Exchange?
Neurol 53:598-604, Visser,L.H.,et al, 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Guillain-Barre Syndrome
Lancet 352:635-641, Hahn,A.F., 1998
The Spectrum of Antecedent Infections in Guillain-Barre Syndrome
Neurol 51:1110-1115, Jacobs,B.C.,et al, 1998
CIDP:Clinical Features & Responses to Trtm in 67 Consecutive Pts with/without a Monoclonal Gammopathy
Neurol 48:321-328, Gorson,K.G.,et al, 1997
Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997
Idiopathic Dysautonomia Treated with Intravenous Gammaglobulin
Lancet 347:28-29, Heafield,M.T.E.,et al, 1996
Reversible Encephalopathy with Cerebral Vasospasm in a Guillain-Barre Syndrome Patient Treated with Intravenous Immunoglobulin
Neurol 46:250-251, Voltz,R.,et al, 1996
Liver Function Disturbances in Guillain-Barre Syndrome:A Prospective Longitudinal Study in 100 Patients
Neurol 46:96-100, Oomes,P.G.,et al, 1996
Pilot Trial of Immunoglobulin Versus Plasma Exchange in Patients with Guillain-Barre Syndrome
Neurol 46:100-103, Bril,V.,et al, 1996
Childhood Leukemia:Central Nervous System Abnormalities During and After Treatment
AJNR 17:295-310, Chen,C-Y.,et al, 1996
Campylobacter Jejuni Infection and Anti-GM1 Antibodies in Guillain-Barre Syndrome
Ann Neurol 40:181-187, Jacobs,B.C.,et al, 1996
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Cytomegalovirus Infection and Guillain-Barre Syndrome:The Clinical, Electrophysiologic, and Prognostic Features
Neurol 47:668-673, Visser,L.H.,et al, 1996
Intravenous IgG in Guillain-Barre Syndrome
BMJ 313:376-377, Hughes,R.A.C., 1996
Lyme Radiculoneuritis Treated with Intravenous Immunoglobin
Neurol 46:1174-1175, Crisp,D.&Ashby,P., 1996
Acute Paresis of Extraocular Muscles Associated with IgG Anti-GQ Antibody
Ann Neurol 39:668-672, Yuki,N., 1996
Campylobacter Jejuni Infection and Guillain-Barre Syndrome
NEJM 333:1374-1379, 14151995., Rees,J.H.,et al, 1995
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994